المؤلفون: Seefat MR; Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlandsī., Stege CAM; Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlandsī., Lissenberg-Witte BI; Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Levin MD; Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Timmers GJ; Internal Medicine, Amstelland Hospital, Amstelveen, the Netherlands., Hoogendoorn M; Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Ypma PF; Hematology, Haga Hospital, Den Haag, the Netherlands., Klein SK; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands; Department of Internal Medicine, Meander Medical Center, Amersfoort, the Netherlands., Velders GA; Internal Medicine, Ziekenhuis Gelderse Vallei, Ede, the Netherlands., Westerman M; Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands., Strobbe L; Internal Medicine, Gelre Hospital Zutphen, Zutphen, the Netherlands., Durdu-Rayman N; Internal Medicine, Franciscus Hospital location Vlietland, Schiedam, the Netherlands., Davidis-van Schoonhoven MA; Internal Medicine, Beatrix Hospital, Gorinchem, the Netherlands., van Kampen RJW; Internal Medicine-hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Dijk AC; Internal Medicine, St Jansdal Hospital, Harderwijk, the Netherlands., Koster A; Internal Medicine, Viecuri Medical Center, Venlo, the Netherlands., Silbermann MH; Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands., van der Spek E; Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands., Beeker A; Internal Medicine, MBA Spaarne Gasthuis, Hoofddorp, the Netherlands., Erjavec Z; Internal Medicine, Treant ziekenhuis, Hoogeveen, the Netherlands., de Graauw NCHP; Internal Medicine, Bravis ziekenhuis, Roosendaal, the Netherlands., Leys MBL; Hematology and Oncology, Maasstad ziekenhuis, Rotterdam, the Netherlands., Sonneveld P; Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlandsī., van de Donk NWCJ; Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlandsī., Nasserinejad K; Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlandsī., Blommestein HM; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands., Cucchi DGJ; Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlandsī; Internal Medicine, Franciscus Hospital location Vlietland, Schiedam, the Netherlands., Zweegman S; Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlandsī. Electronic address: s.zweegman@amsterdamumc.nl.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Aug; Vol. 207, pp. 114153. Date of Electronic Publication: 2024 Jun 06.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/psychology , Quality of Life* , Bortezomib*/therapeutic use , Bortezomib*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Frailty*, Humans ; Aged ; Male ; Female ; Prospective Studies ; Aged, 80 and over ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Melphalan/therapeutic use ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Prednisone/adverse effects ; Frail Elderly

المؤلفون: Stege CAM; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. c.stege@amsterdamumc.nl., Nasserinejad K; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Klein SK; Department of Internal Medicine, Meander Medical Center, Amersfoort, the Netherlands.; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Timmers GJ; Department of Internal Medicine, Amstelland Hospital, Amstelveen, the Netherlands., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Ypma PF; Department of Hematology, Haga Hospital, The Hague, the Netherlands., Nijhof IS; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Velders GA; Department of Internal Medicine, Ziekenhuis Gelderse Vallei, Ede, the Netherlands., Strobbe L; Department of Internal Medicine, Gelre Hospital, Zutphen, the Netherlands., Durdu-Rayman N; Department of Internal Medicine-Hematology, Franciscus Hospital location Vlietland, Schiedam, the Netherlands., Westerman M; Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands., Davidis-van Schoonhoven MA; Department of Internal Medicine, Beatrix Hospital, Gorinchem, the Netherlands., van Kampen RJW; Department of Internal Medicine/Hematology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Beeker A; Department of Internal Medicine, MBA Spaarne Gasthuis, Hoofddorp, the Netherlands., Koster A; Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands., Dijk AC; Department of Internal Medicine, St Jansdal Hospital, Harderwijk, the Netherlands., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands., Leys RBL; Department of Hematology and Oncology, Maasstad Ziekenhuis, Rotterdam, the Netherlands., Silbermann MH; Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands., Groen K; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., van der Burg-de Graauw NCHP; Department of Internal Medicine, Bravis ziekenhuis, Roosendaal, the Netherlands., Sinnige HAM; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, the Netherlands., van der Hem KG; Department of Internal Medicine, Zaans Medical Center, Zaandam, the Netherlands., Levenga H; Department of Internal Medicine, Groene Hart Hospital, Gouda, the Netherlands., Bilgin YM; Department of Internal Medicine, Admiraal de Ruijter Hospital, Goes, the Netherlands., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Zweegman S; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.

المصدر: Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2715-2719. Date of Electronic Publication: 2021 Feb 15.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Geriatric Assessment/*methods , Multiple Myeloma/*mortality, Aged ; Aged, 80 and over ; Follow-Up Studies ; Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Prognosis ; Prospective Studies ; Survival Rate

المؤلفون: Stege CAM; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Nasserinejad K; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands., Bilgin YM; Department of Internal Medicine, Admiraal de Ruijter Hospital, Goes, the Netherlands., Kentos A; Department of Hematology, Centre Hospitalier Jolimont, Haine-Saint-Paul, Belgium., Sohne M; Department of Internal Medicine/Hematology, St Antonius Hospital, Nieuwegein, the Netherlands., van Kampen RJW; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Ludwig I; Department of Hematology, Bernhoven Hospital, Uden, the Netherlands., Thielen N; Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands., Durdu-Rayman N; Department of Internal Medicine-Hematology, Franciscus Hospital location Vlietland, Schiedam, the Netherlands., de Graauw NCHP; Department of Internal Medicine, Bravis Hospital, Roosendaal, the Netherlands., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., de Waal EGM; Department of Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands., Vekemans MC; Department of Hematology, St Luc Hospital, Bruxelles, Belgium., Timmers GJ; Department of Internal Medicine, Amstelland Hospital, Amstelveen, the Netherlands., van der Klift M; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Soechit S; Department of Hematology, Reinier de Graaf Groep, Delft, the Netherlands., Geerts PAF; Department of Internal Medicine, Deventer Hospital, Deventer, the Netherlands; Currently Isala, Zwolle, the Netherlands., Silbermann MH; Department of Internal Medicine, Tergooi Hospital, Hilversum, the Netherlands., Oosterveld M; Department of Internal Medicine, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Nijhof IS; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Klein SK; Department of Internal Medicine, Meander Medical Center, Amersfoort, the Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands., Zweegman S; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Sep 01; Vol. 39 (25), pp. 2758-2767. Date of Electronic Publication: 2021 May 04.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Quality of Life*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Frail Elderly/*statistics & numerical data , Multiple Myeloma/*drug therapy, Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Boron Compounds/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Follow-Up Studies ; Glycine/administration & dosage ; Glycine/analogs & derivatives ; Humans ; Male ; Multiple Myeloma/pathology ; Prognosis ; Prospective Studies ; Survival Rate

المؤلفون: de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Hussaarts KGAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., de With M; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Halteren HK; Department of Internal Medicine, Admiraal de Ruyter Hospital, Goes, The Netherlands., van der Burg-de Graauw NCHP; Department of Internal Medicine, Bravis Hospital, Roosendaal, The Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van Gelder T; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., van Leeuwen RWF; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

المصدر: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Jun; Vol. 105 (6), pp. 1456-1461. Date of Electronic Publication: 2019 Feb 10.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms/*blood , Drug Interactions/*physiology , Esomeprazole/*blood , Phenylurea Compounds/*blood , Proton Pump Inhibitors/*blood , Pyridines/*blood, Aged ; Biological Availability ; Colorectal Neoplasms/drug therapy ; Cross-Over Studies ; Esomeprazole/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Phenylurea Compounds/therapeutic use ; Proton Pump Inhibitors/therapeutic use ; Pyridines/therapeutic use